Tamara van Donge

Chapter 1 20 References 1. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. Vol 20: Springer; 2011. 2. Rowland M, Tozer TN, Derendorf H, Schmidt S. Rowland’and Tozer’s Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Wolters Kluwer; 2020. 3. Peck RW. Precision medicine is not just genomics: the right dose for every patient. Annual review of pharmacology and toxicology. 2018;58:105-122. 4. Halpern SA. American pediatrics: The social dynamics of professionalism, 1880-1980. Univ of California Press; 1988. 5. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. New England Journal of Medicine. 2003;349(12):1157-1167. 6. Gunderman RB. Inspiring advocacy: Abraham Jacobi. Pediatric radiology. 2020;50(2):164-165. 7. Allegaert K, Van De Velde M, van den Anker J. Neonatal clinical pharmacology. Pediatric Anesthesia. 2014;24(1):30-38. 8. Allegaert K, van den Anker JN. Adverse drug reactions in neonates and infants: a population‐ tailored approach is needed. British journal of clinical pharmacology. 2015;80(4):788-795. 9. van den Anker J. Paediatric extrapolation: the panacea for paediatric drug development? British journal of clinical pharmacology. 2019;85(4):672. 10. Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. British journal of clinical pharmacology. 2015;79(3):395-404. 11. van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. The Journal of Clinical Pharmacology. 2018;58:S10-S25. 12. Mooij MG, de Koning BA, Huijsman ML, de Wildt SN. Ontogeny of oral drug absorption processes in children. Expert opinion on drug metabolism & toxicology. 2012;8(10):1293-1303. 13. Hines R. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. International journal of pharmaceutics. 2013;452(1-2):3-7. 14. de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert opinion on drug metabolism & toxicology. 2011;7(8):935-948. 15. Savage WJ, Everett AD. Biomarkers in pediatrics: children as biomarker orphans. PROTEOMICS– Clinical Applications. 2010;4(12):915-921. 16. Group BDW, Atkinson Jr AJ, Colburn WA, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology & therapeutics. 2001;69(3):89-95. 17. Bennett MR, Nehus E, Haffner C, Ma Q, Devarajan P. Pediatric reference ranges for acute kidney injury biomarkers. Pediatric nephrology. 2015;30(4):677-685. 18. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatric nephrology. 2011;26(10):1843- 1849. 19. Vieux R, Hascoet J-M, Merdariu D, Fresson J, Guillemin F. Glomerular filtration rate reference values in very preterm infants. Pediatrics. 2010;125(5):e1186-e1192. 20. Ceriotti F. Establishing pediatric reference intervals: a challenging task. In: Oxford University Press; 2012. 21. Colantonio DA, Kyriakopoulou L, Chan MK, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clinical chemistry. 2012;58(5):854-868.